Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Eric Scott Christenson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5261-6083; OpenAlex author ID A5049837751; NIH RePORTER profile ID 15174179. Sources: ClinicalTrials.gov.

Their work

Papers
7 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
2
Labs led
0
Collaborators
34
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 2 papers, 1 grant · 2025: 1 paper, 1 trial · 2026: 2 papers, 1 grant

Papers 7

  1. Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gassur.2026.102359↗
  2. The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II… Co-author DOI 10.1038/s41467-026-69294-3↗
  3. CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer clinical trial. Co-author DOI 10.1016/j.isci.2024.111569↗
  4. Neutrophils in pancreatic ductal adenocarcinoma: bridging preclinical insights to clinical prospects for improved therapeutic strategies. First author DOI 10.1080/1744666x.2024.2348605↗
  5. The impact of KRAS mutations on the clinical outcome and immune response following immunotherapy for pancreatic cancer. Co-author DOI 10.21037/apc-24-2↗
  6. Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2767-9764.crc-22-0343↗
  7. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. Co-author DOI 10.1016/s1470-2045(19)30795-8↗

Trials 1

  1. Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer Principal investigator NCT06782932↗

Grants 2

  1. Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial R01CA197296↗
  2. Clinical Accelerator Initiative grant: Eric Christenson AWARD lustgarten:2024-eric-christenson-clinical-accelerator-initiative-grant-er

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lei Zheng · 4 shared papers, 1 shared grant, 2024–2026 · strength 1.80
  2. Elizabeth M. Jaffee · 4 shared papers, 1 shared grant, 2020–2026 · strength 1.67
  3. William Reece Burns · 1 shared paper, 1 shared grant, 2026 · strength 1.11
  4. Dung Thi Le · 3 shared papers, 2022–2026 · strength 0.60
  5. Daniel A. Laheru · 3 shared papers, 2022–2026 · strength 0.60
  6. Kelly J. Lafaro · 2 shared papers, 2026 · strength 0.45
  7. Richard Andrew Burkhart · 2 shared papers, 2026 · strength 0.45
  8. Michael Jon Pishvaian · 2 shared papers, 2026 · strength 0.45
  9. Katherine M. Bever · 2 shared papers, 2022–2026 · strength 0.40
  10. Robert A. Anders · 2 shared papers, 2025–2026 · strength 0.37
  11. Hao Wang · 2 shared papers, 2022–2026 · strength 0.35
  12. Keyu Li · 1 shared paper, 2024 · strength 0.31
  13. Yi Cong Jin · 1 shared paper, 2024 · strength 0.31
  14. Jin He · 1 shared paper, 2026 · strength 0.25
  15. Christopher R. Shubert · 1 shared paper, 2026 · strength 0.25
  16. Sagar D. Patel · 1 shared paper, 2026 · strength 0.25
  17. Matthew Z. Guo · 1 shared paper, 2026 · strength 0.25
  18. MS, PA-C Amy Hacker-Prietz · 1 shared paper, 2026 · strength 0.20
  19. Ding Ding · 1 shared paper, 2026 · strength 0.20
  20. Valerie Lee · 1 shared paper, 2026 · strength 0.20
  21. Joseph M. Herman · 1 shared paper, 2026 · strength 0.20
  22. Arsen Osipov · 1 shared paper, 2026 · strength 0.20
  23. Amol Kumar Narang · 1 shared paper, 2026 · strength 0.20
  24. Nilofer Saba Azad · 1 shared paper, 2020 · strength 0.19
  25. Dimitrios N. Sidiropoulos · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.